Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors

NCT04309968 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: Drug: SYHA1801

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.